RxDoctor Payments Data

Karen Mockler, MD

Family Medicine · Dadeville, ALNPI 1407879083

Payments from drug & device makers

$876in general payments, 2019–2025

Across 43 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$155
  • Novo Nordisk$118
  • AstraZeneca$107
  • Radius Health, Inc.$101
  • Amneal Pharmaceuticals LLC$68
  • Amgen$44
  • plus $282 from 13 others

What the payments were for

  • Food & beverage$70380%
  • Education$15518%
  • Gifts$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$876 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$2,526
Medicare patients
32
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$239,194
JanuviaSitagliptin Phosphate200$159,493
OzempicSemaglutide126$116,664
EliquisApixaban71$64,412
RybelsusSemaglutide50$53,780
MounjaroTirzepatide49$53,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$50,949
MyrbetriqMirabegron59$41,753
SynthroidLevothyroxine Sodium500$39,888
LinzessLinaclotide54$37,899
FarxigaDapagliflozin Propanediol38$33,944
JardianceEmpagliflozin50$31,224
TrulicityDulaglutide31$27,619
Spiriva RespimatTiotropium Bromide34$27,101
JanumetSitagliptin Phos/Metformin Hcl38$24,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$118$170,444176 claims
Lilly USA, LLCMounjaro, Trulicity$37$80,77580 claims
AbbVieSynthroid, Linzess$42$77,787554 claims
GSKTrelegy Ellipta, Breo Ellipta$17$72,58591 claims
PfizerEliquis$37$64,41271 claims
Astellas Pharma US IncMyrbetriq$155$41,75359 claims
AstraZenecaFarxiga$107$33,94438 claims
AmgenProlia$44$18,94811 claims
Sumitomo Pharma America, Inc.Gemtesa$14$16,36126 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$68$7,450610 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Dadeville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →